posted
the thinking is that this has great news, drops 3 days 10 cents today, hitting 32 DMA at it gonnna bounce and hopefully run, (sttc yesterday) thats the play....
PASADENA, Calif.--(BUSINESS WIRE)--Dec. 20, 2004--Sanguine Corp. (OTC Bulletin Board: SGNC - News), a bio-pharmaceutical company focused on the development of an oxygen-carrying synthetic substitute for human red blood cells, announced its budgets are now in place to plan FDA testing and to select a manufacturer of PHER-O2 in early 2005. The company will convene a meeting in January of its Medical Advisory Board to finalize the details. Presentations will be made by Sanguine's regulatory affairs consultants and by the company's recent Medical Board addition, Dr. Robert Kwun. The presentations will detail the protocol planning for an FDA indication for retinal surgery and for a yet unnamed second indication. The approach will be to demonstrate the safety and efficacy of PHER-O2 for both procedures.
Additionally, the company is in discussions with a company to manufacture PHER-O2. The intent will be to manufacture PHER-O2 for pre-clinical sales to universities and others in 2005. Several groups desirous of using PHER-O2 in multiple areas have contacted the company. Additional information relating to the manufacture and sales of PHER-O2 will be released, as they become available.
The product PHER-O2 is in its pre IND phase with Cardinal Health and the University of Alberta. The company has heard from the FDA and the FDA has determined that the trial approach is as a device, which I understand from Cardinal is a very good thing.
Best regards Michael Dancy
-------------------- Let's watch it go up!
IP: Logged |
posted
PASADENA, Calif., Dec 05, 2006 (BUSINESS WIRE) -- Sanguine Corporation (OTC Bulletin Board: SGNC), a bio-pharmaceutical company focused on the development of an oxygen-carrying synthetic substitute for human red blood cells and numerous other areas requiring oxygen profusion, in collaboration with its FDA testing contractors and development team, met with the FDA to discuss the Company's regulatory path. The Company believes that its product, PHER-O2, is appropriately suited for whole organ (pancreas and kidney), preservation for transplantation.
PRIBO, a well known BioPharma Industry analyst, reported that the annual organ and tissue transplantation market in the U.S. was estimated at $11.7 billion in 2005 and is expected to rise at an average annual growth rate (AAGR) of 5.2% to $15.1 billion by 2010. The transplantation market was estimated at just under $5 billion in 2005 and is expanding at an AAGR of 4.8%. The fastest growing sector is small bowel (intestine) transplantation. Kidney and liver transplantation will account for 78% of the total in 2005. The U.S. tissue transplantation market totaled about $6.8 billion in 2005. It is projected to grow at an AAGR of 5.5%, to $8.9 billion in 2010. A copy of the report may be found at: www.piribo.com/publications/biotechnology/organ_tissue_ transplantation_alternatives.html (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)
Dr. Thomas C. Drees, Ph.D. - President and CEO remarked, "We are extremely excited to have finally met with the FDA related to our testing program. As I have mentioned previously, the use of PHER-O2 for pancreas and/or islet cell preservation in treating diabetes (the fastest growing disease in the world) is particularly attractive because the product is used ex-vivo (outside the body), which should simplify the regulatory process. We are most interested in generating a device indication that presumably would be the most expedient route toward our ability to market PHER-O2. As indicated by numerous BioPharma sources, the transplantation market is substantially large. Our plan is to use PHER-O2 in conjunction with other transplantation transport materials to provide an oxygenated environment to aid in the longevity of whole organs. We look forward to having our development team continue its work with the FDA to finalize the most appropriate and direct regulatory path. We feel the meeting with the FDA was quite successful."
For information related to the Sanguine Corporation, contact Investor Relations: Michael Dancy, 801-746-3570, email: medancy*allwest.net, or visit: www.sanguine-corp.com.
Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.
SOURCE: Sanguine Corporation
CONTACT: For Sanguine CorporationMichael Dancy, 801-746-3570 (Investor Relations)e-mail: medancy*allwest.netwww.sanguine-corp.com
Copyright Business Wire 2006
-------------------- Let's watch it go up!
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
